Lydia Abásolo, MD; Margarita Blanco, MD, PhD; Javier Bachiller, MD; Gloria Candelas, MD, PhD; Paz Collado, MD, PhD; Cristina Lajas, MD, PhD; Marcelino Revenga, MD; Patricia Ricci, MD; Pablo Lázaro, MD, PhD; Maria Dolores Aguilar, MD, PhD; Emilio Vargas, MD, PhD; Benjamín Fernández-Gutiérrez, MD, PhD; César Hernández-García, MD, PhD; Loreto Carmona, MD, PhD; Juan A. Jover, MD, PhD
Grant Support: In part by grants from the Fondo de Investigaciones Sanitarias of the Spanish Ministry of Health numbers FIS 98/1050 and 00/0201.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Juan A. Jover, MD, PhD, Servicio de Reumatología, Hospital Clínico San Carlos, Calle Profesor Martín Lagos s/n, 28040 Madrid, Spain; e-mail, firstname.lastname@example.org.
Current Author Addresses: Drs. Abásolo, Blanco, Candelas, Lajas, Vargas, Fernández-Gutiérrez, Hernández-García, Carmona, and Jover: Servicio de Reumatología, Hospital Clínico San Carlos, Calle Profesor Martín Lagos s/n, 28040 Madrid, Spain.
Drs. Bachiller and Revenga: Servicio de Reumatología, Hospital Ramón y Cajal, Carretera de Colmenar, Km 9.1, 28034 Madrid, Spain.
Drs. Collado and Ricci: Servicio de Reumatología, Hospital Severo Ochoa, Avenida Orellana s/n 28911, Madrid, Spain.
Drs. Lázaro and Aguilar: TAISS (Técnicas Avanzadas de Investigación en Servicios de Salud), C/ Cambrils 41, 28034 Madrid, Spain.
Author Contributions: Conception and design: C. Hernández-García, J.A. Jover, E. Vargas.
Analysis and interpretation of the data: L. Abásolo, L. Carmona, C. Hernández-García, J.A. Jover, C. Lajas, P. Lázaro, E. Vargas.
Drafting of the article: L. Abásolo, L. Carmona, B. Fernández-Gutiérrez, C. Hernández-García, J.A. Jover.
Critical revision of the article for important intellectual content: L. Abásolo, M.D. Aguilar, L. Carmona, B. Fernández-Gutiérrez, C. Hernández-García, J.A. Jover, C. Lajas, P. Lázaro.
Final approval of the article: L. Abásolo, L. Carmona, B. Fernández-Gutiérrez, C. Hernández-García, J.A. Jover.
Provision of study materials or patients: M. Blanco, J. Bachiller, G. Candelas, P. Collado, C. Lajas, M. Revenga, P. Ricci.
Statistical expertise: L. Abásolo, M.D. Aguilar, L. Carmona, C. Hernández-García, E. Vargas.
Obtaining of funding: J.A. Jover.
Administrative, technical, or logistic support: J. Bachiller, M. Blanco, G. Candelas, P. Collado, C. Lajas, M. Revenga, P. Ricci.
Collection and assembly of data: L. Abásolo, J. Bachiller, M. Blanco, G. Candelas, P. Collado, C. Lajas, M. Revenga, P. Ricci.
Musculoskeletal disorders (MSDs) are a frequent cause of work disability, accounting for productivity losses in industrialized societies equivalent to 1.3% of the U.S. gross national product.
To evaluate whether a population-based clinical program offered to patients with recent-onset work disability caused by MSDs is cost-effective.
Randomized, controlled intervention study. The inclusion and follow-up periods each lasted 12 months.
Three health districts in Madrid, Spain.
All patients with MSD-related temporary work disability in 1998 and 1999.
The control group received standard primary care management, with referral to specialized care if needed. The intervention group received a specific program, administered by rheumatologists, in which care was delivered during regular visits and included 3 main elements: education, protocol-based clinical management, and administrative duties.
Efficacy variables were 1) days of temporary work disability and 2) number of patients with permanent work disability. All analyses were done on an intention-to-treat basis.
13 077 patients were included in the study, 7805 in the control group and 5272 in the intervention group, generating 16 297 episodes of MSD-related temporary work disability. These episodes were shorter in the intervention group than in the control group (mean, 26 days compared with 41 days; P < 0.001), and the groups had similar numbers of episodes per patient. Fewer patients received long-term disability compensation in the intervention group (n = 38 [0.7%]) than in the control group (n = 99 [1.3%]) (P < 0.005). Direct and indirect costs were lower in the intervention group than in the control group. To save 1 day of temporary work disability, $6.00 had to be invested in the program. Each dollar invested generated a benefit of $11.00. The program's net benefit was in excess of $5 million.
The study was unblinded.
Implementation of the program, offered to the general population, improves short- and long-term work disability outcomes and is cost-effective.
Abásolo L, Blanco M, Bachiller J, Candelas G, Collado P, Lajas C, et al. A Health System Program To Reduce Work Disability Related to Musculoskeletal Disorders. Ann Intern Med. ;143:404–414. doi: 10.7326/0003-4819-143-6-200509200-00005
Download citation file:
Published: Ann Intern Med. 2005;143(6):404-414.
Healthcare Delivery and Policy, Hematology/Oncology, Rheumatology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use